The NHP Foundation and Henson Development Company Open the Doors to Park Heights Senior Apartments
Development is first phase of $400M Neighborhood Revitalization Plan
BALTIMORE, May 22, 2025 /PRNewswire/ -- The NHP Foundation (NHPF), a national not-for-profit provider of affordable housing, partnered with The Henson Development Company (Henson), the City of Baltimore, the Maryland Department of Housing and Community Development (DHCD), and Park Heights Renaissance Community Development Corporation (CDC) to celebrate the ribbon-cutting of The Terraces at Park Heights—a $52 million development delivering 100 affordable one- and two-bedroom homes for seniors in Northwest Baltimore.
This milestone marks the first phase of a sweeping transformation of the 17.3-acre Park Heights Master Redevelopment Area (MRA), designed to revitalize a historically under-invested community into a vibrant, mixed-income, multi-generational neighborhood. The master redevelopment plan includes NHPF and Henson's 90-unit single-family home community, affordable multifamily building and new green spaces. This is expected to further support the neighborhood revitalization efforts which include the new Enoch Pratt Free Library as well as an overhaul of Pimlico Racecourse.
Distinguished guests at the ceremony included Maryland Governor Wes Moore and First Lady of Maryland Dawn Moore, Baltimore Mayor Brandon M. Scott, and First Lady of Baltimore City Hana Scott, Councilwoman Sharon Green Middleton, Housing Commissioner Alice Kennedy, Delegate Sandy Rosenberg, Senator Antonio Hayes, Park Heights Renaissance CEO Yolanda Jiggetts, and Elizabeth Tatum, Acting Director, Mayor's Office of Recovery Programs, and Delegates Malcolm Ruff and Sean Stinnett.
"Since taking office, we've invested more than $75 million into Park Heights to create jobs, grow the economy, and open pathways to work, wages, and wealth for Baltimoreans," said Gov. Wes Moore. "This project marks the next chapter in our work, and it will transform the city by ensuring seniors have access to affordable housing and a safe, vibrant community. When we say this is Maryland's decade and Baltimore's time, it's partnerships like this one that show us what that looks like."
Major Announcements Unveiled at the Event:
The overall master-planned community will be called Cloverbrook Green. Cloverbrook was the first horse to win the Preakness Stakes that had been bred and trained in Maryland. The community will offer an array of "green" features including solar-powered common areas and energy-efficient appliances.
90+ single-family homes with a targeted construction start of 2026.
A 59-unit affordable multifamily rental building will be named The Anderson, commemorating George "Spider" Anderson's legacy.
A new sculpture of Anderson—one of only two African American jockeys to win the Preakness in its 150-year history—was unveiled along with other outdoor artwork created by Art with a Heart, a local organization dedicated to using art to enrich lives, bridge divides, and forge the leaders of tomorrow. George "Spider" Anderson was the first African American to win the Preakness Stakes on May 10, 1889 and May 10th, 2025, the date of the Ribbon cutting was the 136th anniversary of his win.
A mural by Baltimore based multi-hyphenate artist LaToya Peoples that honors the history of people of color in the racing industry and celebrates Baltimore's heritage.
"We see this as a unique opportunity to merge Baltimore's rich history with innovative, forward-thinking development that will reestablish this area as a cornerstone of economic and social activity," said Dana Henson, Vice President, Principal, The Henson Development Company, Inc. "There's a story here waiting to be retold, and we're excited to craft a narrative that blends the area's historic vibrancy with new opportunities for growth, connection, and celebration."
The event featured citations from both the Mayor's office and Senator Chris Van Hollen and representatives from the many vendors responsible for the project's completion: Southway Builders, Torti Gallas & Partners, STV Inc., D.W. Kozera, and Environmental Health Consultants.
The celebration aligned with the 150th running of the Preakness Stakes and the 4th Annual George "Spider" Anderson Music & Arts Festival, reinforcing the neighborhood's cultural ties to Baltimore's racing history.
"You can see my family's home from the Terraces, so this groundbreaking is especially meaningful to me," said Baltimore Mayor Brandon M. Scott. "For many years, folks thought a project like this one, in Park Heights, was impossible. But here we are. This is the story of a neighborhood that never gave up, that stayed committed, and that came together to do the impossible. I couldn't be prouder to be a son of Park Heights—especially today—and I'm grateful to each and every member of the community who helped make this a reality."
Funding partners for the development include:
$8.7M – U.S. Department of Housing and Urban Development (HUD)
$22.5M – Tax credit equity from R4 Capital and Aetna, a CVS Health Company
$13.3M – City of Baltimore
$5.4M – Maryland CDA
$2.1M – Deferred developer fees
Additionally, through community quarterback Park Heights Renaissance, Governor Moore's Office of Children funded the ENOUGH Grant Program which contributed $300,000 toward a new onsite maker space, providing hands-on creative programming for residents and the surrounding community.
"In partnership with our state, city and local partners, we are helping to restore Park Heights' position as one of the most prominent and sought after neighborhoods in the City," said Mansur Abdul-Malik, Senior Vice President, NHPF. "The new maker space reflects our commitment to investing in people and places which we feel are the two most important ingredients for any neighborhood revitalization effort."
Community-Driven, Sustainable Design
The Terraces at Park Heights incorporates rooftop, carport, and gazebo-mounted solar panels, battery backup power, and meet the National Green Building Standards. Amenities include a fitness center, library, computer lab, coffee bar, and lounge areas, along with original artwork and photography celebrating the neighborhood's horseracing legacy.
Resident services will be provided onsite by Operation Pathways, NHPF's dedicated resident services subsidiary.
"Housing is the foundation of strong communities. We are committed to building public-private partnerships that drive long-term change," said Eric Price, President and CEO of NHPF, "Though the road hasn't always been easy, we have remained true to our commitment—to the City and to the residents of Park Heights—to help make this a place where people want to live, grow, and thrive."
About The NHP Foundation (NHPF)The NHP Foundation (NHPF) is a 501(c)(3) not-for-profit real estate corporation founded in 1989. With over three decades of experience in affordable housing acquisition, investment, development and construction, NHPF's team brings together deep knowledge of real estate fundamentals, attention to changing resident and community needs, and the expertise required to make sound investment decisions. We are also committed to providing equitable, tailored resident services programs, powered by our subsidiary, Operation Pathways, which offers Family-Centered Coaching to families facing poverty and hardship. Through strategic partnerships with financial institutions, the public sector, faith-based organizations, and other nonprofits, NHPF currently owns and operates 63 properties across 16 states and the District of Columbia serving over 25,000 residents. For more information, please visit www.nhpfoundation.org.
About The Henson Development CompanyTHE HENSON DEVELOPMENT COMPANY, INC. (THC), a 100% family owned and operated minority-owned business enterprise, is a fully integrated real estate developer, consultant and program manager based in Baltimore, Maryland. The president and founder of THC is Dan Henson, a successful developer who has a distinguished private and public sector career in housing. Founded in 2000, the company is committed to providing full service real estate development services in urban and progressive communities. THC has had particularly detailed experience with re-energizing former public housing developments into mixed-income, mixed-use communities for more sustainable and stable communities, offering a comprehensive vehicle to revitalize neighborhoods that nurture and support an improved quality of life for the families who reside there. THC has worked on or is currently working on real estate development projects totaling over $600 Million – 3,000 units in Baltimore, Maryland, Washington, D.C. and Florida. Additionally, THC serves as a consultant on numerous assignments across the country.
View original content to download multimedia:https://www.prnewswire.com/news-releases/the-nhp-foundation-and-henson-development-company-open-the-doors-to-park-heights-senior-apartments-302463534.html
SOURCE NHP Foundation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer
Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting Data show low rates of treatment-related adverse events, signaling human kallikrein 2 (KLK2) as a novel, highly specific target CHICAGO, June 1, 2025 /PRNewswire/ -- Johnson & Johnson announced today new data from a Phase 1 study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific antibody that activates T-cells to harness the body's immune system against prostate cancer cells, showing promise in patients with advanced disease who have progressed after multiple lines of therapy. These first data on pasritamig, from the first-in-human study, demonstrate that pasritamig appears well-tolerated and exhibits a promising antitumor activity in patients with metastatic castration-resistant prostate cancer (mCRPC), highlighting the potential of KLK2 as a novel target for T-cell engagement in advanced disease.1 These data were presented as an oral presentation (Abstract #5017) at the 2025 American Society of Clinical Oncology Annual Meeting and published simultaneously in The Journal of Clinical Oncology. Pasritamig is a novel T-cell engager designed to bind both CD3 on T-cells and KLK2—a prostate-specific antigen with minimal expression outside of the prostate. Pasritamig activates T-cells by binding to CD3 and directing them to KLK2- expressing tumor cells, engaging the body's immune system to specifically target these cancerous cells. This differentiated approach aims to deliver a targeted treatment for patients with advanced prostate cancer, while potentially reducing the high-grade toxicities historically associated with T-cell engagers. "These first-in-human results for pasritamig are highly encouraging, demonstrating that KLK2 is a viable target for T-cell engagers in metastatic castration-resistant prostate cancer," said Capucine Baldini*, M.D., Ph.D., Drug Development Department (DITEP), Institut Gustave Roussy, and presenting author. "The data show a promising safety profile, with manageable adverse events and no AEs leading to treatment discontinuations or ICANS observed, with 40 percent of patients having no treatment-related AEs at all. Given the limited treatment options for mCRPC, these findings support further investigation of pasritamig and the role of KLK2-targeted T-cell therapies as a potential new approach for patients with aggressive disease." "Metastatic castration-resistant prostate cancer remains one of the most difficult stages of prostate cancer to treat, particularly for patients who haven't responded well to previous treatments," said Jeff Infante, M.D., Vice President of Early Clinical Development and Translational Research at Johnson & Johnson Innovative Medicine. "This investigational approach underscores our commitment to developing innovative and practice-changing medicines that are well-tolerated and can be easily administered in community practice settings." The Phase 1 first-in-human study (NCT04898634) evaluated 174 patients with ages ranging from 36 to 89 years old and on average having received four prior therapies (range 1-13). The recommended phase 2 dose (RP2D) of pasritamig was 3.5mg on day 1, 18mg on day 8, 300mg intravenously on day 15 and then once every six weeks. The RP2D safety group also included patients treated once every three weeks as the toxicity profiles were very similar. The RP2D efficacy group only included patients treated at the RP2D once every six weeks.1 Within the RP2D safety group (n=45), treated once every three or six weeks, 100 percent had previously received androgen receptor pathway inhibitors, 75.6 percent had undergone taxane chemotherapy, and 37.8 percent had been treated with Lutetium 177 vipivotide tetraxetan prostate-specific membrane antigen radioligand therapy.1 The most common treatment- related adverse events (TRAEs) were Grade 1/2 infusion-related reactions (24.4 percent), Grade 1 cytokine release syndrome (CRS) presenting as fever only (8.9 percent, no steroid or tocilizumab was administered) and no reports of higher grade CRS. No TRAEs leading to treatment discontinuation or dose reduction were reported and no immune effector cell-associated neurotoxicity syndrome (ICANS) was observed. Grade 3 TRAEs were infrequent with 4.4 percent of patients reporting transient AST/ALT increases and neutropenia. There were no dose-limiting toxicities reported. The favorable safety profile of the RP2D regimen enabled convenient outpatient administration on a patient-friendly, once-every-six-weeks schedule.1 Of the patients in the RP2D efficacy group (n=33), treated once every six weeks, 42.4 percent achieved a 50 percent or greater reduction in their prostate-specific antigen (PSA) levels with a median rPFS of 7.9 months (95 percent confidence interval [CI] 2.9, not estimable [NE]) and 21.2 percent of patients continuing therapy. Treatment with pasritamig showed durable disease control and rPFS that compares favorably to historical data in heavily pretreated patients with mCRPC.1 Metastatic castration-resistant prostate cancer occurs in a significant portion of prostate cancer patients, with many progressing despite initial therapies.2 Overall survival from diagnosis of mCRPC patients ranges from 13.5 to 31.6 months, and lower in patients who have progressed on therapy.3 Treatment options remain limited, underscoring the urgent need for safer and more effective therapies.4 About Pasritamig (JNJ-78278343)Pasritamig (JNJ-78278343) is an investigational T-cell-engaging bispecific antibody (bsAb) targeting human kallikrein 2 (KLK2) on prostate cancer cells and CD3 on T-cells. This approach is being evaluated in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC), a patient population with limited treatment options. About Metastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic castration-resistant prostate cancer (mCRPC) is a challenging and aggressive stage of prostate cancer where the disease progresses despite androgen deprivation therapy.2 Patients often experience metastasis to bones and lymph nodes, leading to poor outcomes and limited treatment options, including chemotherapy and second-line hormone therapies.5 The median overall survival ranges from 13.5 to 31.6 months depending on the site of metastasis, with a typical range of 15–36 months across the broader population.3,6 Survival rates can vary significantly depending on factors such as prior treatment history, disease burden, and response to therapy. The need for more effective treatments is critical, as the disease continues to impact a large number of men globally, with mCRPC being responsible for a substantial number of prostate cancer-related deaths. About Johnson & JohnsonAt Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at or at Follow us at @JNJInnovMed. Janssen Research & Development, LLC, Janssen Biotech, Inc., Janssen Global Services, LLC and Janssen Scientific Affairs, LLC are Johnson & Johnson companies. Cautions Concerning Forward-Looking StatementsThis press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of JNJ-78278343. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Source: Johnson & Johnson *Dr. Capucine Baldini has provided consulting, advisory, and speaking services to Johnson & Johnson; Dr. Baldini has not been paid for any media work. 1 Baldini, C., et al. Phase 1 Study Results of Pasritamig (JNJ-78278343) in Metastatic Castration-Resistant Prostate Cancer. 2025 American Society of Clinical Oncology Annual Meeting. June 2025.2 Scher, H. I., et al. (2016). "Treatment of castration-resistant prostate cancer: Current and future strategies." Nature Reviews Clinical Oncology, 13(10), 577-590.3 Wallace KL, Landsteiner A, Bunner SH, Engel-Nitz NM, Luckenbaugh AN. Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States. Cancer Causes Control. 2021;32(12):1365-1374. doi:10.1007/s10552-021-01484-44 Ravi P, Mateo J, Lorente D, et al. Clinical prognostic factors and management of metastatic castration-resistant prostate cancer: a population-based study. PLoS One. 2015;10(10):e0139440. doi:10.1371/ Ryan, C. J., et al. (2015). "Abiraterone acetate in metastatic prostate cancer: A new era." Journal of Clinical Oncology, 33(10), 1051-1060.6 Kawahara, T., Saigusa, Y., Yoneyama, S. et al. Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide. BMC Cancer 23, 214 (2023). Media contacts:Oncology Media Relations oncology_media_relations@ Investor contact:Lauren Johnsoninvestor-relations@ U.S. Medical Inquiries +1 800 526-7736 View original content to download multimedia: SOURCE Johnson & Johnson Sign in to access your portfolio
Yahoo
16 hours ago
- Yahoo
Walz: Democrats need to be a ‘little meaner'
Minnesota Gov. Tim Walz (D) said his fellow party members need to be a bit more harsh in upcoming elections to put an end to political intimidation. After an unsuccessful bid for the vice presidency in November, Walz has shared staunch criticism of Elon Musk and other officials within the Trump administration. 'I'm getting called out on this because I called Donald Trump a wannabe dictator — it's because he is. It's because he is,' Walz said Saturday during his keynote address for the South Carolina Democratic Party Convention. He said people alleged that his comments were 'mean.' 'Well, maybe it's time for us to be a little meaner. Maybe it's time for us to be a little more fierce, because we have to ferociously push back on this,' Walz said, urging critics to rebuke the Trump administration's policies. Walz's words were echoed by Maryland Gov. Wes Moore (D) during his remarks at the annual South Carolina Democrats' Blue Palmetto Dinner Friday night. 'I want to be clear: We can and we must condemn Donald Trump's reckless actions. But we would also be foolish not to learn from his impatience,' Moore, a first-term governor, said during his roughly 30-minute speech to the state party's officials and activists. 'Donald Trump doesn't need a study to dismantle democracy or use the Constitution like a suggestion box. Donald Trump doesn't need a white paper to start arbitrary trade wars that raise the cost of virtually everything in our lives,' he added. Walz and Moore also made an appearance at Rep. Jim Clyburn's (D-S.C.) annual fish fry Friday night, an event known to be dazzled by presidential hopefuls. The Maryland governor said he would not run for the Oval Office next election cycle but party members have floated him as a viable leader for 2028. On Saturday, Walz said that any work geared towards ensuring a Democratic win in the next presidential campaign would need to start soon. 'It starts this Saturday as us starting to organize. Donald Trump ran for president for four years after he got beat in 2020. The Republican Party ran for four years. Their school board members ran for four years. All of those things were happening,' the Minnesota governor said. 'And what I know about our party is we know how to work. We're people with grit and resilience. We know how to get things done,' he added. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
17 hours ago
- Yahoo
Casio to Release New MT-G Featuring an Original Frame Co-Created by Humans and AI
Newly Developed Structure Fusing Different Materials TOKYO, May 27, 2025 /PRNewswire/ -- Casio Computer Co., Ltd. announced today the latest addition to the G-SHOCK brand of shock-resistant watches: the MTG-B4000. This new timepiece features a distinctive frame developed in a process of collaboration between human designers and AI technology. The MTG-B4000 joins the MT-G line of timepieces, all of which utilize a unique construction that makes the most of the properties of both metal and resin. The new MTG-B4000 is a shock-resistant watch featuring a distinctive frame that was developed in a process of collaboration between human designers and generative AI and uses a combination of different materials. For the first time in a Casio consumer timepiece, generative AI technology was integrated into the development process. In pursuit of innovative craftsmanship, designers employed this advanced technology as a creative tool to explore new design possibilities and conquer the challenge of realizing a complex, unconventional structure which would have been difficult to achieve using traditional methods. Starting with design proposals from human designers, AI conducted load simulations using decades of accumulated data on shock-resistant construction for G-SHOCK. It then proposed optimal structural configurations by evaluating factors such as structural strength, material characteristics, and machinability. These AI-generated designs were refined through repeated testing and adjustments by skilled human hands, resulting in a frame that delivers the G-SHOCK signature ruggedness with a distinctive, unconventional aesthetic only achievable through AI collaboration. A new approach was also introduced by integrating the band connection parts into the frame. This allows the frame to directly absorb loads applied to the band, reducing impact on the center case and further enhancing shock resistance. The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. Any use of such marks and logos by Casio Computer Co., Ltd. is under license. View original content to download multimedia: SOURCE CASIO COMPUTER CO., LTD Sign in to access your portfolio
